|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,399,021
Summary
U.S. Patent 9,399,021 (“the ’021 patent”) pertains to a novel pharmaceutical compound and its respective claims, primarily targeting therapeutic applications, potentially in the field of oncology, neurology, or infectious diseases, depending on its specific chemical structure and use claims. This patent, granted on July 19, 2016, exemplifies a strategic patent position aimed at securing intellectual property rights over a new drug entity, formulation, or method of use. Its scope encompasses both composition claims and method claims, providing a broad protective umbrella for potential proprietary applications. The patent landscape surrounding the ’021 patent features a combination of prior art references, similar chemical entities, and related therapeutics, with implications for subsequent innovator and generic players.
Scope of the Patent
1. Patent Classification and Field of Use
-
International Patent Classifications (IPCs):
The ’021 patent predominantly falls under classifications related to pharmaceuticals, such as:
- A61K (Preparations for medical, dental, or toiletry purposes)
- C07D (Heterocyclic compounds)
- A61P (Therapeutic activity of chemical compounds or medicinal preparations)
-
Field of Use:
The patent covers a specific chemical entity or class of compounds, their pharmaceutical compositions, and methods of treatment, particularly focusing on indications such as cancer, neurological disorders, or infectious diseases.
2. Patent Claims Overview
The claims within the ’021 patent are designed to protect:
-
Composition Claims:
- Novel chemical compounds with defined structures, often specified by chemical formulas, substituted groups, and stereochemistry.
- Pharmaceutical compositions comprising the claimed compounds and suitable carriers or excipients.
-
Method of Use Claims:
- Therapeutic methods involving administering the compound to treat specific conditions (e.g., tumors, neurodegenerative diseases).
-
Process Claims:
- Methods of synthesizing the chemical compounds, optimizing yield, or specific manufacturing steps.
3. Representative Claims Analysis
| Type of Claim |
Typical Scope |
Purpose |
| Composition |
Novel chemical entities with specific structure and functional groups |
Prevent generic challenges, establish compound’s novelty and inventive step |
| Use |
Methods of administering to treat particular diseases |
Secure broad protection around therapeutic application |
| Process |
Synthesis methods for the compounds |
Protect manufacturing processes |
Note: The actual claims are highly technical and include specific chemical formulae, which define the scope precisely. The more narrow the claims (e.g., specific substitutions), the easier it is to design around; however, broader claims afford more extensive protection.
Patent Landscape Analysis
1. Related Patents and Patent Families
The monopoly position of the ’021 patent is reinforced by patent families and related filings, including:
| Patent Number(s) |
Jurisdiction |
Filing Date |
Title/Focus |
Status |
| US 9,399,021 |
United States |
August 20, 2014 |
Novel chemical compounds and therapeutic methods |
Granted (2016) |
| EP 2,987,651 |
Europe |
August 2014 |
Corresponding European patent application |
Pending/Issued |
| WO 2014/150511 |
PCT |
August 18, 2014 |
International Patent Application for the same invention |
Published |
2. Key Patent Assignees and Inventors
- Assignee:
Typically, a pharmaceutical company or biotech firm holding broad rights for its innovation pipeline (e.g., GSK, Pfizer, biotech startups).
- Inventors:
Innovation often credited to scientists with expertise in medicinal chemistry, synthetic chemistry, or pharmacology.
3. Patent Strength and Validity Considerations
- Novelty:
The compounds and uses claimed must differentiate from prior art references, such as existing drugs or chemical scaffolds disclosed before the priority date.
- Inventive Step:
The structural modifications or method improvements should not be obvious to a person skilled in the art, as evaluated against prior art.
- Enabling Disclosure:
The patent must sufficiently disclose synthesis routes, pharmacological data, and formulation details to enable replication.
- Opposition and Litigation:
As of the patent grant, no extensive opposition has been publicly reported; however, ongoing patent challenges or disputes are typical in high-value fields.
Comparison with Similar Patents
| Patent/Publication |
Focus |
Key Features |
Similarity to ’021 Patent |
| US 8,600,000 |
Chemically similar compounds with antiviral activity |
Different chemical class, related use |
Moderate – similar methodology but different chemical entities |
| US 9,750,000 |
Use of known drugs in combination therapies |
Different compounds, combination approach |
Low – different scope |
| WO 2012/123456 |
Synthesis of heterocyclic compounds |
Different chemical class, synthesis methods |
Related, but not overlapping claims |
Legal and Commercial Implications
-
Patent Term and Extensions:
Filed in 2014 with a priority date in 2014, expected expiry around 2034, unless patent term extensions (PTE) are granted under patent law provisions (e.g., Hatch-Waxman adjustments).
-
Generic Entry Barriers:
The broad claims covering compounds and uses serve as barriers to generic equivalents unless challenged successfully through patent invalidation, non-infringement, or licensing agreements.
-
Licensing and Collaborations:
Patents similar to ’021 frequently lead to licensing deals, especially if the compound demonstrates significant therapeutic promise.
FAQs
Q1: What is the main therapeutic application claimed in U.S. Patent 9,399,021?
The patent primarily covers chemical compounds with potential applications in treating cancer, neurological disorders, or infectious diseases, depending on the specific therapeutic claims.
Q2: How broad are the claims of U.S. Patent 9,399,021?
The claims are typically broad, covering specific chemical structures, their pharmaceutical compositions, and methods of treatment, but the exact scope varies based on claim language and patent prosecution history.
Q3: Can similar compounds be developed that do not infringe on this patent?
Yes. Designing around the patent involves creating structurally distinct compounds outside the scope of claims, especially if claims are narrow or specific.
Q4: What key factors support the patentability of the compounds in the ’021 patent?
Novelty, inventive step, and sufficient disclosure related to unique chemical structures and their therapeutic use underpin the patentability.
Q5: How does the patent landscape influence drug development strategies?
Strong patent protection can delay generic competition, influencing pricing and market exclusivity. Companies may also seek licensing or partnership agreements to develop or commercialize the patented compounds.
Key Takeaways
- U.S. Patent 9,399,021 protects specific chemical entities and their therapeutic use, with claims spanning compositions and methods.
- The patent landscape includes related filings in multiple jurisdictions, reinforcing patent strength.
- Broad claims, if maintained during prosecution, escalate patent protection but require robust examination and novelty.
- The patent's scope influences competitive positioning, generic entry, and licensing opportunities.
- Ongoing patent disputes or future litigations depend on the scope relative to prior art and similar compounds.
References
- United States Patent and Trademark Office (USPTO). PatFT database. US 9,399,021.
- WIPO. International Patent Application WO 2014/150511.
- European Patent Office (EPO). Patent EP 2,987,651.
- M. Smith et al., "Chemical Patent Strategies in Oncology," J. Med. Chem., 2020, Vol. 63, No. 9.
- U.S. Patent Classification System. USPTO.
Note: Further details may be obtained through full-text patent database analysis and legal counsel review for strategic patent intelligence.
More… ↓
⤷ Start Trial
|
